Physician profile
Taylor Leblanc
NPI 1366912537
$48,353.99
in general payments reported to CMS, 2019-2025
16 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $453 · 2022: $716 · 2023: $7,739 · 2024: $16K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Food and Beverage: $3,627 · Travel and Lodging: $3,326 · Consulting Fee: $3,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,045.00 |
| Food and Beverage | $3,627.34 |
| Travel and Lodging | $3,325.51 |
| Consulting Fee | $3,187.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32,865.42 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13,002.79 | 2021-2025 | Caplyta |
| Indivior INC. | $585.85 | 2021-2025 | Perseris, Sublocade |
| Alkermes, INC. | $461.58 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Janssen Pharmaceuticals, INC | $232.06 | 2021-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $223.37 | 2021-2024 | Austedo Xr, Uzedy |
| Sumitomo Pharma America, INC. | $204.49 | 2023-2025 | Gemtesa |
| Braeburn INC. | $197.26 | 2023-2025 | Brixadi |
| Otsuka America Pharmaceutical, INC. | $164.18 | 2021-2025 | Rexulti |
| Corcept Therapeutics | $121.60 | 2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $94.09 | 2024-2025 | Cobenfy |
| Gilead Sciences, INC. | $67.15 | 2024 | Epclusa |
| Vanda Pharmaceuticals INC. | $58.03 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $43.34 | 2025 | |
| Sunovion Pharmaceuticals INC. | $16.54 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Masimo Corporation | $16.24 | 2023 | Patient Safetynet System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Leblanc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.